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clinical practice due to limitations of the Utrecht applicator 
were excluded. This yielded the 'pre-plan' needle 
configuration. 
The 'pre-plan' and 'expert opinion' needle configurations were 
then compared respectively with the 'ideal' needle placement 
for the first fraction of BT. The latter was determined using a 
similar method with applicator modeling, but this time using 
the delineated MR scan of the first BT fraction (with 
applicator in place). Note that the HR-CTV delineated on the 
pre-MRI will be different to the one delineated on the MR 
scan of the first BT fraction, and also that the 'ideal' needle 
configuration will be different from the one clinically 
applied. 
The similarity of both the 'pre-plan' and the 'expert opinion' 
needle configuration as compared to the 'ideal' plan was 
quantified using Dice’s similarity coefficient. 
Fig 1. Sagittal view of applicator modeling and needle 
placement on delineated MRIs for 'pre-plan' (above) and 'ideal 
plan' (below). HR-CTV is shown in red. 
 
 
Results: The average Dice’s similarity coefficient ±1SD 
between the 'pre-plan' needles and 'ideal' needles was 0.48 ± 
0.44, while that obtained between the 'expert opinion' 
needles and the 'ideal' needles was 0.56 ± 0.32. 
Conclusions: The needles predicted by the 'pre-plan' are as 
comparable to an ideal needle placement as those predicted 
in the current 'expert opinion' scenario, but performing a 
'pre-plan' simulation of needles may well be more efficient as 
compared to expert discussion.  
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Purpose/Objective: The purpose of this retrospective 
analysis was to compare contact x-ray Brachytherapy 
(Papillon) doses and treated volumes with HDR endoluminal 
Brachytherapy for more advanced rectal cancer.  
Materials and Methods: 
Background:HDR rectal Brachytherapy is typically used as a 
boost following pre-operative RT. Patients are treated using 
our standard prescription of 10Gy in one fraction with a 
standard prescription depth of 10 mm from the surface of the 
OncoSmart flexible rectal applicator. The treatment length 
and channels to be loaded are determined by the clinician 
using 2D orthogonal imaging taken after applicator insertion. 
The applicator is reconstructed in the treatment planning 
system, where standard library plans are then used to plan 
the treatment. Source weighting is currently tapered 
symmetrically at either end of the treated length for most 
treatments. 
Methods: This analysis was undertaken retrospectively on 173 
patients treated since October 2004. Comparisons of the 
treated volume when using different treatment lengths, 
number of catheters used and source weighting were made. 
Currently 2D imaging is used in HDR Brachytherapy, so 
volumes treated for each patient prescription and treatment 
condition were calculated using an external contour in 
Oncentra Masterplan. Dose prescription points (A to H) are 
situated at the centre of the applicator, midway between 
active catheters, and 10 mm from the applicator surface. 
Results: Only patients planned using multiple catheters were 
examined as part of this analysis. The majority of patients 
were treated with 5 or 6 channels (86.7%). It can be seen 
that the volume treated increases with the number of 
treatment catheters used.  
 
 
8 patients (4.6%) were treated without source weighting. 
Using library plan data it was shown that treated volumes 
were reduced by an average of 18% when tapered source 
weighting was used. The largest volume reductions occurred 
when fewer catheters were used. The dose at the surface of 
the applicator was found to increase as the treatment length 
reduced, with an average increase of 8 Gy (range 7.7 Gy to 
8.6 Gy) as the treatment length changed from 10 cm to 4 cm. 
Dose points B to E were used as a measure of surface dose for 
the 5 catheter treatment and were situated at the applicator 
surface. 
 
Conclusions: Our results showed that the volumes treated 
with HDR endoluminal Brachytherapy were greater than those 
treated with Papillon (where <5cc is covered by the 
prescription isodose). We now modify our Brachytherapy 
treatment to use a lower number of channels (4 catheters) 
and use source weighting to reduce the volumes treated. We 
also hope to change our Brachytherapy treatment regime to 
7Gy in 3 fractions in patients with bulky residual tumour 
following EBCRT who are not suitable for a Papillon boost and 
move towards 3D planning with CT and/or MR imaging.  
   
  
